Industry ยท Oct 2026
Specialty & Generic Drug Manufacturer stocks ranked by gap to the model's fair value
Faircurve's model values 13 specialty & generic drug manufacturer stocks. 6 of them are ranked below by the gap between the model's fair value and the last close, as of 31 Oct 2026: 1 read as Undervalued, 5 as Fairly valued and 0 as Overvalued. The median gap across the ranked names is +4.6%. The widest gaps above the price are VTRS (+22.1%), ANIP (+8.3%), AMRX (+5.0%). The widest below it are ALKS (-11.1%), LNTH (-2.2%), ZTS (+4.2%).
Valuations as of . Prices are the closes of 3 Nov 2026. The gap is the model's fair value against the price: a positive gap means the fair value is above the price. It states what the model concluded, not where the price goes next.
The ranking
| Rank | Company | Last close | Model fair value | Gap | Model verdict | Quality score | Market value |
|---|---|---|---|---|---|---|---|
| 1 | VTRS Viatris Inc. | $18.92 | $23.11 | +22.1% | Undervalued | 28 | $21.9B |
| 2 | ANIP ANI Pharmaceuticals, Inc. | $72.28 | $78.25 | +8.3% | Fairly valued | 81 | $1.7B |
| 3 | AMRX Amneal Pharmaceuticals, Inc. | $20.21 | $21.22 | +5.0% | Fairly valued | 59 | $6.9B |
| 4 | ZTS Zoetis Inc. | $82.99 | $86.45 | +4.2% | Fairly valued | 70 | $32.9B |
| 5 | LNTH Lantheus Holdings, Inc. | $100.80 | $98.59 | -2.2% | Fairly valued | 70 | $6.6B |
| 6 | ALKS Alkermes plc | $45.69 | $40.62 | -11.1% | Fairly valued | 43 | $7.6B |
The Global Pulse
Faircurve's market note, in your inbox each market day
The Global Pulse is Faircurve's note after each US session: what moved, in plain words. No account needed.
Valued but not ranked
These 7 names are valued but not ranked, for one of four reasons: the model grades the evidence as low or has not graded it yet, the inputs are under review, the gap is wider than 60%, or the valuation is more than three weeks old. The numbers are shown for reference.
| Company | Last close | Model fair value | Gap | Why it is not ranked | Quality score | Market value |
|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals, Inc. | $27.12 | $27.90 | +2.9% | Low evidence grade | $1.2B | |
| COLL Collegium Pharmaceutical, Inc. | $23.73 | $23.98 | +1.1% | Low evidence grade | $775M | |
| ELAN Elanco Animal Health Incorporated | $24.57 | $22.21 | -9.6% | Low evidence grade | 43 | $11.5B |
| INDV Indivior Pharmaceuticals Inc | $36.28 | $35.52 | -2.1% | Low evidence grade | $4.4B | |
| PAHC Phibro Animal Health Corporation | $37.65 | $37.94 | +0.8% | Low evidence grade | 56 | $1.6B |
| PCRX Pacira BioSciences, Inc. | $36.39 | $36.66 | +0.7% | Low evidence grade | $1.5B | |
| SUPN Supernus Pharmaceuticals, Inc. | $28.15 | $42.16 | +49.8% | Low evidence grade | $2.4B |